89 SrCl2治疗骨癌及骨转移癌所致骨痛的疗效观察  

Efficacy of 89SrCl2 in the treatment of bone pain caused by bone cancer and metastatic bone tumors

作　　者：高云翔 黄省利[2] 付战利 吕昌伟 GAO Yun-xiang;HUANG Sheng-li;FU Zhan-li;LYU Chang-wei(Department of Orthopaedic Surgery,Northwest University Affiliated Hospital,The Third Hospital of Xi'an,Xi'an 710018,China;Department of Orthopaedics,The Second Affiliated Hospital of Xi'an Jiaotong University,Xi'an 710004,China)

机构地区：[1]西北大学附属医院/西安市第三医院骨外科,西安710018 [2]西安交通大学第二附属医院骨科,西安710004

出　　处：《中国肿瘤临床与康复》2020年第10期1170-1172,共3页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的探讨骨癌及骨转移癌所致骨痛患者采用89 SrCl2治疗的临床疗效。方法选取2019年6月至2020年4月间西北大学附属医院收治的96例骨癌及骨转移癌所致骨痛患者,均采用89 SrCl2内照射法治疗,评估治疗效果。结果治疗后,患者骨痛Ⅰ级+Ⅱ级82例,总有效率为85.4%,其中肺癌骨痛缓解总有效率为75.8%,乳腺癌为89.3%,食道癌为93.8%,骨癌及其他癌为89.5%。共42例(43.8%)患者产生反跳痛,25例患者疼痛情况无变化,17例患者新增病灶疼痛。发病时间为治疗后5~15d,持续7d内症状自行消失。治疗后,患者血小板(72.5±6.4)×10^9/L,白细胞(2.8±0.5)×10^9/L,存在轻度异常,2~3周后逐步恢复正常。患者均未发生严重不良反应。结论骨癌及骨转移癌所致骨痛患者采用89 SrCl2治疗,临床疗效较好,不良反应发生率较低,值得临床推广应用。Objective To study the clinical efficacy of 89 SrCl2 in the treatment of bone pain caused by bone cancer and metastatic bone tumors.Methods Ninety-six patients with bone pain caused by bone cancer and metastatic bone tumors who received treatment at Northwest University Affiliated Hospital from June 2019 to April 2020 were selected.89 SrCl2 irradiation(internal exposure)was performed on all the patients.The therapeutic efficacy was evaluated and analyzed.Results After the treatment,82 patients were diagnosed with gradeⅠandⅡbone pain with the overall efficacy rate of 85.4%.Among them,the overall efficacy rate was 75.8%for lung cancer,89.3%for breast cancer,93.8 for esophageal cancer and 89.5%for bone cancer and other cancers.Rebound tenderness occurred in 42 patients(43.8%).No change in pain was noticed in 25 patients.New lesions-induced pain was observed in 17 patients and it occurred at 5 to 15 d after the treatment and the symptoms disappeared spontaneously within 7 d.After the treatment,the platelet level was(72.5±6.4)×10^9/L and the level of white cell count was(2.8±0.5)×10^9/L with slight abnormalism,which returned to normal after 2 to 3 weeks,and no side effects occurred in the patients.Conclusion 89 SrCl2 is effective in the treatment of bone pain caused by bone cancer and metastatic bone tumors.The incidence of adverse reactions is low.It is worthy of clinical application.

关 键 词：骨肿瘤 骨转移肿瘤 骨痛 89 SrCl2 

分 类 号：R738.1[医药卫生—肿瘤]